Article
Improved transplant survival and long-term disease outcome in children with MHC class II deficiency.
Blood - 19 Mar 2020
Lum Su Han, Anderson Claire, McNaughton Peter, Engelhardt Karin Regine, MacKenzie Brigid, Watson Helen, Al-Mousa Hamoud, Al-Herz Waleed, Al-Saud Bandar, Mohammed Reem, Al-Zahrani Daifulah M, Alghamdi Hamza Ali, Goronfolah Loie, Nademi Zohreh, Habibollah Sahar, Flinn Aisling M, Shillitoe Benjamin, Owens Stephen, Williams Eleri, Emonts Marieke, Hambleton Sophie, Abinun Mario, Flood Terrence, Cant Andrew, Gennery Andrew R, Slatter Mary
Abstract excerpt
MHC class II deficiency is a rare, but life-threatening, primary combined immunodeficiency. Hematopoietic cell transplantation (HCT) remains the only curative treatment for this condition, but transplant survival in the previously published result was poor. We analyzed the outcome of 25 patients with MHC class II deficiency undergoing first HCT at Great North Children's Hospital between 1995 and 2018. Median age...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.